antiinflammatory agent 1

Anti-inflammatory agent 1 is a chemical compound designated for reducing inflammation, structurally characterized by a [carboxyl acid], [oxygen], and [hydrocarbon] ring, with notable efficacy in mitigating inflammatory responses.

Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory compound. It inhibits the MAPK and NF-κB signaling pathways by preventing the phosphorylation of IκB-α and blocking the nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 also reduces the production of NO (IC50: 0.5 μM) and the secretion of TNF-α, IL-6, and IL-1β.

Anti-inflammatory agent 102 (Compound 11a) is an orally effective anti-inflammatory compound. It exerts its effects by inhibiting the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. This agent displays significant anti-inflammatory activity by suppressing the release of NO, ROS, and inflammatory cytokines such as IL-6, TNF-α, and IL-1β. Anti-inflammatory agent 102 is applicable in research concerning inflammatory diseases, including ulcerative colitis (UC).

Anti-inflammatory agent 101 (Compound C04) is an orally active anti-inflammatory agent with notable anti-lipid accumulation, anti-inflammatory, and anti-fibrotic properties. It functions by reducing fatty acid uptake, enhancing fatty acid oxidation, and alleviating inflammation, making it applicable in the study of NASH and related liver fibrosis.

Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. It inhibits TNF-α synthesis and release in the U937 human macrophage cell line with an IC50 of 0.024 nM. Additionally, Anti-inflammatory agent 104 reduces eosinophil levels in rat lungs by 63%.

Anti-inflammatory agent 105 (Compound 12) is an anti-inflammatory compound. It inhibits the synthesis and release of TNF-α in the human macrophage cell line U937, with an IC50 of 0.124 nM.

Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial agent used in tuberculosis (TB) research, inhibiting the growth of Mtb H37Rv and M299 with MIC50 values of 2.3 and 7.8 μM, respectively. This compound also suppresses the expression of iNOS, thereby inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial agent used in tuberculosis (TB) research. It inhibits the growth of Mtb H37Rv and M299 with MIC 50 values of 1.3 and 6.9 μM, respectively. Additionally, it reduces inflammation by suppressing iNOS expression and inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].

Anti-inflammatory agent 16 (compound 14) is a potent peptidomimetic that significantly reduces the expression levels of TNFα, NO, CD40, and CD86 [1].

Anti-inflammatory agent 10 is a tilomisole-based benzimidazole-thiazole derivative that is orally active. anti-inflammatory agent 10 is more active against COX-2 enzymes than COX-1.

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Anti-inflammatory agent 12 is a pentacyclic triterpene compound that showed a significant bias in LPS-induced inflammatory responses (IC50: 2.22 μM). anti-inflammatory agent 12 has potential for use in inflammatory disease research.

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 19 inhibits NO (IC50: 36.00 μM). anti-inflammatory agent 19 exhibits an inhibitory effect on HMGB1-induced late inflammatory responses. anti-inflammatory agent 19 can be used to study late inflammatory diseases such as Coronavirus disease (COVID-19), sepsis, etc.

Meloxicam D4 is deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity,(Target:COX-1; IC50: 36.6 μM ;(Target:COX-2; IC50: 0.49 μM).

Protizinic acid inhibits phospholipase A2 (PLA2) with an IC 50 of 210 μM. Protizinic acid has antiinflammatory and antipyretic activity which is an orally active non-steroidal antiinflammatory agent [1] [2].